The molecular mechanism of DLBCL according to MYC associatd factor X (MAX)

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K16200
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 49020:Human pathology-related
• Research Institution: Saitama Medical University
• Principal Investigator: Yamashita Takahisa 埼玉医科大学, 医学部, 講師 (60464749)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: DLBCL / MYC / MAX

Outline of Final Research Achievements

In this study, we conducted an investigation into the regulatory mechanism of MYC and MYC associated factor X (MAX) in diffuse large B-cell lymphoma (DLBCL). Immunohistochemistry(IHC) for MYC and MAX was performed on approximately 160 DLBCL cases. The IHC result and four public gene expression data indicate that the stratification of DLBCL prognosis by two expression profiles is possible. Particularly in the group with high expression of MYC and low expression of MAX, we observed an association with double-hit lymphoma-related molecules, suggesting that high MYC expression and low MAX expression could serve as poor prognostic markers for DLBCL.

Free Research Field

腫瘍病理学

Academic Significance and Societal Importance of the Research Achievements

本研究ではMYCとその関連分子であるMAXを用いてDLBCLの層別化を行い、MYC高発現、MAX低発現症例ではDouble hit signatureとの関連性が高く、予後不良であることを見出した。DLBCLでは網羅的な遺伝子異常や遺伝子発現解析による層別化が現在の研究の中心となっているが、検査が高額かつその結果の解釈に時間がかかり、臨床応用には至っていない。本研究では、MYCとMAXの免疫染色といった安価かつ速やかな方法による予後不良症例の抽出が可能であり、臨床応用されれば社会的な意義は高いものと思われる。